Events | December 07, 2021
Oncologists call for adoption of tech innovations to treat cancer
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Subscribe To Our Newsletter & Stay Updated
